Skip to content
Screener

BioMarin Pharmaceuticals BMRN Other operating expenses

Other operating expenses at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$227.59M+10.6%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$42M+31.9%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$27.27M+2.8%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$57.38M+37.6%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$62.67M+20.7%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.88B+2.0%
Enterprise value$15.19B+37.7%
P/E33×-35.6×
P/S3.5×-0.3×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherOperatingIncomeExpenseNet.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
INCOME FROM OPERATIONS110,920276,887240,560500,780
Interest income10,48018,82733,04037,840
Interest expense(63,295)(2,679)(78,253)(5,542)
Other income, net3,2794,8337,2402,879
INCOME BEFORE INCOME TAXES61,384297,868202,587535,957
Provision for income taxes16,62257,33652,298109,739
NET INCOME$44,762$240,532$150,289$426,218
EARNINGS PER SHARE, BASIC$0.23$1.25$0.78$2.23

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's other operating expenses?
BioMarin Pharmaceuticals (BMRN) reported other operating expenses of $3.28M in Q2 2026.
How has BioMarin Pharmaceuticals's other operating expenses changed year-over-year?
BioMarin Pharmaceuticals's other operating expenses decreased by 32.2% year-over-year, from $4.83M to $3.28M.
What is the long-term trend for BioMarin Pharmaceuticals's other operating expenses?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's other operating expenses has grown at a -6.6% compound annual growth rate (CAGR), from $11.85M to $9M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about BioMarin Pharmaceuticals's other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude